Mary White Scharf

Dr. Mary E. White-Scharf is Senior Vice President of Research at BioTransplant Incorporated, a company that is developing products to address the current challenges in transplantation medicine.  She joined the company in 1991 as Director of Monoclonal Antibodies and led the project to develop BTI-322^®, an anti-CD2 monoclonal antibody, the humanized version of which is currently in clinical trials for treatment of psoriasis.  In 1995, she was promoted to Vice President of Research and assumed leadership of the XenoMune™ program, a system being developed to enable transplantation of porcine organs into humans.  Prior to joining BioTransplant, Dr. White-Scharf held the position of Research Scientist at Repligen, where she led efforts to develop monoclonal antibodies directed against the V3 loop of HIV-1.

	Xenotransplantation and its Associated Safety and Ethical Issues